Patents by Inventor David Bruge

David Bruge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrrolopyridinylpyrimidin-2-ylamine derivatives
    Patent number: 8420820
    Abstract: Compounds of the formula I in which X, R1, R2, R3, R4 and R6 have the meanings indicated in claim 1, are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: April 16, 2013
    Assignee: Merck Patent GmbH
    Inventors: Margarita Wucherer-Plietker, David Bruge, Dirk Finsinger, Ulrich Graedler, Dieter Dorsch, Christina Esdar
  • Tetrahydroquinolines for use as modulators of the mitotic motor protein Eg5
    Patent number: 8207345
    Abstract: Compounds of the formula (I), in which W, R, R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in Claim 1, can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: June 2, 2006
    Date of Patent: June 26, 2012
    Assignee: Merck Patent GmbH
    Inventors: Kai Schiemann, David Bruge, Hans-Peter Buchstaller, Ulrich Emde, Dirk Finsinger, Christiane Amendt, Frank Zenke
  • METHODS FOR THE TREATMENT OF TUMORS WITH INDANE COMPOUNDS
    Publication number: 20120130147
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, and q have the meanings indicated in Claim 1, can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: January 25, 2012
    Publication date: May 24, 2012
    Inventors: Dirk FINSINGER, David Bruge, Hans-Peter Buchstaller, Ulrich Emde, Kai Schiemann, Wolfgang Staehle, Christiane Amendt, Nina Heiss, Frank Zenke
  • Tetrahydroquinoline derivatives
    Patent number: 8110583
    Abstract: Compounds of the formula I, in which s, k, I, W, R1, R2, R3, and U have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours.
    Type: Grant
    Filed: May 31, 2006
    Date of Patent: February 7, 2012
    Assignee: Merck Patent GmbH
    Inventors: Wolfgang Staehle, David Bruge, Kai Schiemann, Dirk Finsinger, Hans-Peter Buchstaller, Frank Zenke, Christiane Amendt
  • Tetrahydroquinolines
    Patent number: 7915416
    Abstract: Disclosed are compounds of formula (I), wherein W, R, R1, R2, R3, R4, R5, R6, and R7 have the meanings indicated in claim 1. Said compounds can be used for the treatment of tumors, among other things.
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: March 29, 2011
    Assignee: Merck Patent GmbH
    Inventors: Kai Schiemann, David Bruge, Hans-Peter Buchstaller, Dirk Finsinger, Wolfgang Staehle, Christiane Amendt, Ulrich Emde, Frank Zenke
  • Oxindoles as kinase inhibitors
    Patent number: 7781475
    Abstract: The present invention relates to oxindoles of the formula I, their use as protein kinase activators or inhibitors, a method for their manufacture, their use for the preparation of a medicament for the treatment of diseases and their use for the manufacture of a pharmaceutical composition.
    Type: Grant
    Filed: May 11, 2006
    Date of Patent: August 24, 2010
    Assignee: Merck Patent GmbH
    Inventors: Lars Thore Burgdorf, David Bruge, Hartmut Greiner, Maria Kordowicz, Christian Sirrenberg, Frank Zenke
  • OXINDOLES AS KINASE INHIBITORS
    Publication number: 20100197757
    Abstract: The present invention relates to oxindoles of the formula I, their use as protein kinase activators or inhibitors, a method for their manufacture, their use for the preparation of a medicament for the treatment of diseases and their use for the manufacture of a pharmaceutical composition.
    Type: Application
    Filed: April 15, 2010
    Publication date: August 5, 2010
    Inventors: Lars Thore BURGDORF, David Bruge, Hartmut Greiner, Maria Kordowicz, Christian Sirrenberg, Frank Zenke
  • SULFAMATOBENZOTHIOPHENE DERIVATIVES
    Publication number: 20100168217
    Abstract: The invention relates to novel compound of the general formula (I), in which R has the meanings indicated in claim 1, to the preparation thereof and to the use thereof as medicaments. The compounds (I) are inhibitors of steroid sulfatase and are used for the treatment of cancer.
    Type: Application
    Filed: November 13, 2007
    Publication date: July 1, 2010
    Applicant: MERCK PATENT GMBH
    Inventors: Wolfgang Staehle, David Bruge, Gerald Scholz, Benoit Rondot, Jean Lafay
  • SULFAMATOBENZOTHIOPHENE DERIVATIVES
    Publication number: 20090286863
    Abstract: The invention relates to novel compound of the general formula (I), in which R has the meanings indicated in Claim 1, to the preparation thereof and to the use thereof as medicaments. The compounds (I) are inhibitors of steroid sulfatase and are used for the treatment of cancer.
    Type: Application
    Filed: June 5, 2007
    Publication date: November 19, 2009
    Inventors: David Bruge, Wolfgang Staehle, Gerald Scholz, Benoit Rondot, Jean Lafay
  • Oxindoles as Kinase Inhibitors
    Publication number: 20090131506
    Abstract: The present invention relates to oxindoles of the formula I, their use as protein kinase activators or inhibitors, a method for their manufacture, their use for the preparation of a medicament for the treatment of diseases and their use for the manufacture of a pharmaceutical composition.
    Type: Application
    Filed: May 11, 2006
    Publication date: May 21, 2009
    Inventors: Lars Thore Burgdorf, David Bruge, Hartmut Greiner, Maria Kordowicz, Christian Sirrenberg, Frank Zenke
  • INDANES
    Publication number: 20090118267
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, and q have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: February 13, 2006
    Publication date: May 7, 2009
    Inventors: Dirk Finsinger, David Bruge, Hans-Peter Buchstaller, Ulrich Emde, Kai Schiemann, Wolfgang Staehle, Christiane Amendt, Nina Heiss, Frank Zenke
  • Tetrahydroquinolines
    Publication number: 20090030028
    Abstract: Disclosed are compounds of formula (I), wherein W, R, R1, R2, R3, R4, R5, R6, and R7 have the meanings indicated in claim 1. Said compounds can be used for the treatment of tumors, among other things.
    Type: Application
    Filed: June 3, 2005
    Publication date: January 29, 2009
    Inventors: Kai Schiemann, David Bruge, Hans-Peter Buchstaller, Dirk Finsinger, Wolfgang Staehle, Christiane Amendt, Ulrich Emde, Frank Zenke
  • Tetrahydroquinoline Derivatives
    Publication number: 20080221118
    Abstract: Compounds of the formula I, in which s, k, I, W, R1, R2, R3, and U have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: May 31, 2006
    Publication date: September 11, 2008
    Inventors: Wolfgang Staehle, David Bruge, Kai Schiemann, Dirk Finsinger, Hans-Peter Buchstaller, Frank Zenke, Christiane Amendt
  • Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5
    Publication number: 20080200451
    Abstract: Compounds of the formula (I), in which W, R, R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: June 2, 2006
    Publication date: August 21, 2008
    Inventors: Kai Schiemann, David Bruge, Hans-Peter Buchstaller, Ulrich Emde, Dirk Finsinger, Christiane Amendt, Frank Zenke
  • Malonamide Derivatives
    Publication number: 20070213374
    Abstract: The present invention relates to malonamide derivatives of formula A-D-B-1, as inhibitors of raf-kinase and the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition.
    Type: Application
    Filed: June 18, 2004
    Publication date: September 13, 2007
    Applicant: Merck Patent GmbH
    Inventors: David Bruge, Hans-Peter Buchstaller, Matthias Wiesner, Dirk Finsinger, Manfred Baumgarth, Christian Sirrenberg, Frank Zenke, Christian Amendt, Matthias Grell